Edition:
United States

Xvivo Perfusion AB (XVIVO.ST)

XVIVO.ST on Stockholm Stock Exchange

93.25SEK
6:58am EDT
Change (% chg)

1.00kr (+1.08%)
Prev Close
92.25kr
Open
92.25kr
Day's High
93.50kr
Day's Low
92.25kr
Volume
7,064
Avg. Vol
29,575
52-wk High
97.75kr
52-wk Low
51.25kr

Latest Key Developments (Source: Significant Developments)

Xvivo Perfusion Q1 EBITDA decreases to SEK 5.0 mln
Tuesday, 25 Apr 2017 02:30am EDT 

April 25 (Reuters) - XVIVO PERFUSION AB :Q1 OPERATING INCOME BEFORE DEPRECIATION AND AMORTIZATION (EBITDA), EXCLUDING ITEMS AFFECTING COMPARABILITY, AMOUNTED TO SEK 5.0 (7.3) MILLION.BOARD OF DIRECTORS HAS RESOLVED UPON A NEW ISSUE OF UP TO 181 MSEK DIRECTED TO INSTITUTIONAL INVESTORS.NET SALES OF NON-DURABLE GOODS IN QUARTER 1 AMOUNTED TO SEK 33.6 (29.1) MILLION, CORRESPONDING TO AN INCREASE OF 16 PERCENT IN SEK.Q1 NET SALES AMOUNTED TO SEK 37.5 (33.5) MILLION, CORRESPONDING TO AN INCREASE OF 12 PERCENT.  Full Article

Xvivo Perfusion: subscription price per new share in private placement at SEK 76.50
Friday, 17 Mar 2017 02:30am EDT 

Xvivo Perfusion AB : Resolves upon an up to about 181 million Swedish crowns ($20.5 million) share issue directed to institutional investors .Subscription price per new share in private placement is set to 76.50 crowns and has been established through book-building.  Full Article

Xvivo Perfusion Q4 adjusted EBITDA drops to SEK 6.7 mln
Wednesday, 8 Feb 2017 02:30am EST 

Xvivo Perfusion Ab : Q4 sales 38.4 million Swedish crowns ($4.32 million) versus 32.7 million crowns year ago .Q4 adjusted EBITDA 6.7 million crowns versus 7.2 million crowns year ago.  Full Article

Xvivo Perfusion Q2 EBITDA ex-items up at SEK 6.9 million
Friday, 15 Jul 2016 02:30am EDT 

Xvivo Perfusion AB : Q2 net sales 34.5 million Swedish crowns ($4.1 million) versus 29.1 million crowns year ago . Q2 EBITDA ex-items 6.9 million crowns versus 4.6 million crowns year ago . Says focus during 2016 is therefore to establish STEEN Solution method as the standard treatment for lung transplantation .Since acquisition of Vivoline company will intensify research and development in cardiac transplantation.  Full Article

Xvivo Perfusion: share warrant program fully subscribed
Friday, 8 Jul 2016 02:30am EDT 

Xvivo Perfusion AB :Upon full exercise of warrants, share capital increase is around 5,500 Swedish crowns ($650) corresponding to a dilution of about 0.9 percent of total number of shares and votes.  Full Article

XVIVO Perfusion extends acceptance period for public offer on Vivoline Medical
Tuesday, 21 Jun 2016 03:50am EDT 

Xvivo Perfusion AB : Extends acceptance period for public offer on Vivoline Medical . Acceptance period is being extended until and including July 14, 2016 .Final payments of consideration are estimated to be made around July 20, 2016.  Full Article

Xvivo Perfusion: XPS contract signed with leading hospital in Alabama, USA
Friday, 17 Jun 2016 02:30am EDT 

Xvivo Perfusion AB : XPS contract signed with leading hospital in Alabama . XPS is the first sold to Alabama, USA .Delivery and installation of XPS will take place in July 2016.  Full Article

Xvivo Perfusion makes recommended public bid for Vivoline Medical
Monday, 18 Apr 2016 02:19am EDT 

Xvivo Perfusion AB:Announces recommended public offer to holders of shares in Vivoline Medical.Offers for every share in Vivoline Medical 1.2921 Swedish crown in cash and 0.1543 shares in Xvivo Perfusion.The consideration corresponds to a value of about 9.32 Swedish crowns per share.Says the total value of the offer amounts to about 128.5 million Swedish crowns.Cash part of the offer is fully funded by Xvivo Perfusion's own current liquid funds.  Full Article

Xvivo Perfusion to deliver XPS to hospital in Boston, US
Friday, 15 Apr 2016 02:30am EDT 

Xvivo Perfusion AB:Signs contract with a hospital in Boston, the United States.Delivery and installation of the XPS is estimated to take place early May 2016.  Full Article

Xvivo says XPS to be delivered to the first clinic in France
Wednesday, 24 Feb 2016 02:30am EST 

Xvivo Perfusion AB:Says Hôpital FOCH in Paris is the first clinic in France that has decided to use XPS.Delivery and installation is estimated to take place at end of March 2016​.  Full Article

More From Around the Web

BRIEF-Xvivo Perfusion Q1 EBITDA decreases to SEK 5.0 mln

* Q1 OPERATING INCOME BEFORE DEPRECIATION AND AMORTIZATION (EBITDA), EXCLUDING ITEMS AFFECTING COMPARABILITY, AMOUNTED TO SEK 5.0 (7.3) MILLION